Brachytherapy
Volume 7, Issue 4 , Pages 286-289 , October 2008

Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone

  • Peter J. Rossi

      Affiliations

    • Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Emory University, 1365 Clifton Avenue, Atlanta, GA 30322. Tel.: +1-404-778-3658; fax: +1-404-778-4139.
    • ,
  • James Urbanic

      Affiliations

    • Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Peter E. Clark

      Affiliations

    • Department of Urology, Vanderbilt University School of Medicine, Nashville, TN
    • ,
  • David L. McCullough

      Affiliations

    • Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • W. Robert Lee

      Affiliations

    • Department of Radiation Oncology, Duke University School of Medicine, Durham, NC

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149
  3. Mettlin CJ, Murphy GP, McDonald CJ, et al. The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999;86:1877–1882
  4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  5. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  6. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440–447
  7. Klein JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. New York: Springer; 1997;
  8. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199–202
  9. Greene FL, American Joint Committee on Cancer , American Cancer Society . AJCC cancer staging handbook from the AJCC cancer staging manual. 6th ed.. New York: Springer; 2002;
  10. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81–94
  11. Grimm PD, Blasko JC, Ragde H, et al. Does brachytherapy have a role in the treatment of prostate cancer?. Hematol Oncol Clin North Am. 1996;10:653–673
  12. Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221–230
  13. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  14. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215–2220
  15. Egawa S, Arai Y, Tobisu K, et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis. 2000;3:269–274
  16. Goluboff ET, Heitjan DF, DeVries GM, et al. Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy. J Urol. 1997;158:1876–1878
  17. Hanks GE, Hanlon AL, Lee WR, et al. Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys. 1996;34:549–553

 Received May 2006; received in revised form September 2006; accepted October 2006.

PII: S1538-4721(08)00609-0

doi: 10.1016/j.brachy.2008.08.004

Brachytherapy
Volume 7, Issue 4 , Pages 286-289 , October 2008

Article Tools

* Image Usage & Resolution